South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...